Antony Newton is Vice President, Business Development at Inivata. At Inivata he is leading new development and commercialization of Inivata’s technology platform for pharmaceutical applications. Prior to Inivata Newton led early commercialization at Personal Genome Diagnostics (PGDx) followed by advisory roles at Natera and Mission Bio. His previous experience includes commercial roles at GE Healthcare, Sigma-Aldrich and Genzyme. Newton has an MS in Applied Immunology from Brunel University London and a PG Dip in business from Anglia Ruskin University, Cambridge, UK.
Clinical Dx Showcase:
Inivata is a leader in liquid biopsy. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late-stage cancer development programs.
The Critical Importance Of Sensitivity In Liquid Biopsy
• All liquid biopsy approaches are not the same – how does the design of approach affect the outcome?
• Why is sensitivity important?
• Liquid biopsies in the continuum of clinical research
• Building a portfolio of MRD assays
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.